Elizabeth Claire Dees

University of North Carolina at Chapel Hill

Also affiliated with UNC Lineberger Comprehensive Cancer Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx”.

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx

Journal of Clinical Oncology(2020)10.1200/jco.19.01866

N/A

3.5DataRank · unranked

102 citations

Robert J. Gray, Joseph A. Sparano, Timothy J. Whelan, Sofia F. Garcia, Betina R. Yanez +14 more

Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer

Breast Cancer Research and Treatment(2022)10.1007/s10549-022-06700-6

N/A

1.1DataRank · unranked

27 citations

Tomás Pascual, Allison M. Deal, Amy Wheless, Charles M. Perou, Elizabeth Claire Dees +2 more

Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer

JAMA Oncology(2023)10.1001/jamaoncol.2023.5424

N/A

0.911DataRank · unranked

34 citations

Vandana G. Abramson, Elizabeth Claire Dees, Payal D. Shah, Tarah J. Ballinger, Claudine Isaacs +12 more

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

npj Breast Cancer(2022)10.1038/s41523-022-00500-3

N/A

0.604DataRank · unranked

55 citations

Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski +21 more

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-003427

N/A

0.500DataRank · unranked

27 citations

Mark G. Woodcock, Amanda E.D. Van Swearingen, Dominic T. Moore, Maria J. Sambade, Sonia J. Laurie +22 more

NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3012

N/A

0.396DataRank · unranked

13 citations

Karen Kelly, Saiama N. Waqar, Elizabeth J. Davis, Geoffrey I. Shapiro, Patricia LoRusso +7 more

NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0519

N/A

0DataRank · unranked

65 citations

Xiaopeng Sun, Paula I. González-Ericsson, Violeta Sánchez, Melinda E. Sanders, Elizabeth C. Wescott +15 more

Quality of Life Outcomes in Breast Cancer Patients Receiving Chemotherapy With or Without Radiation Therapy

Clinical Breast Cancer(2024)10.1016/j.clbc.2024.08.015

N/A

0DataRank · unranked

5 citations

Nathan W Bean, Jacob Hall, Allison M. Deal, Kirsten A. Nyrop, Yara Abdou +10 more

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa148

N/A

0DataRank · unranked

115 citations

Robert J. Gray, Della Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer +23 more

Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer

UNC Libraries(2024)10.17615/nqjk-v350

N/A

0DataRank · unranked

0 citations

Danielle M. File, A.M. Deal, L. Carey, Elizabeth Claire Dees, Charles M. Perou +2 more

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Digital Commons@Becker (Washington University School of Medicine)(2020)10.17615/6e7v-pv95

N/A

0DataRank · unranked

1 citations

Tracy Lively, John A. Olson, Robert J. Gray, Virginia Kaklamani, Della Makower +26 more

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps1102

N/A

0DataRank · unranked

10 citations

Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisín M. Connolly, Erin Roesch, Anosheh Afghahi +15 more

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00473-3

N/A

0DataRank · unranked

16 citations

Kirsten A. Nyrop, Susan L. Strum, Anne K. Knecht, Lisa A. Carey, Katherine E. Reeder‐Hayes +9 more

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer

medRxiv(2022)10.1101/2022.02.10.22270086

N/A

0DataRank · unranked

1 citations

Kirsten A. Nyrop, Susan L. Strum, Anne K. Knecht, Lisa A. Carey, Katherine E. Reeder‐Hayes +9 more

A single-arm feasibility trial of memantine to prevent chemotherapy-related cognitive decline in patients with early breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12109

N/A

0DataRank · unranked

0 citations

Allison M. Deal, Eliza Myung Park, Kate E. Stanton, Yesy E. Lopez, Laura J. Quillen +14 more